Voyager Therapeutics VYGR Cash Flow Statement (2014-2026)

NASDAQ VYGR
$1.76 -0.07 (-3.56%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Voyager Therapeutics Quarterly Cash Flow Statement

Periods 49 quarters
Latest Sep 2026

Voyager Therapeutics reported cash from operations of -$19.67M and free cash flow of -$19.67M for the quarter ended Sep 2026, up 36.7% year over year. This cash flow statement covers 49 quarters of results from Sep 2014 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
5.71M-21.32M-19.09M17.62M-23.63M124.04M-22.21M-25.90M56.40M-11.33M-10.14M-9.04M-34.49M-31.02M-33.38M-27.89M-27.43M-27.94M-24.47M-24.69M
Depreciation and DepletionDep. & Depletion
1.52M2.81M1.20M1.34M0.84M1.08M1.09M0.95M1.34M1.20M1.39M1.13M1.01M1.01M1.07M0.93M1.09M0.93M0.91M0.84M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
1.52M2.81M1.20M1.34M0.84M1.08M1.09M0.95M1.34M1.20M1.39M1.13M1.01M1.01M1.07M0.93M1.09M0.93M0.91M0.84M
Share-based CompensationStock Comp.
1.65M2.27M2.46M2.19M2.35M2.50M2.63M2.88M3.05M3.50M3.96M3.43M3.74M3.67M4.13M3.46M3.52M2.49M2.60M2.60M
Gains from Sales and DivestituresGains Divest
-0.04M-0.08M-0.02M-0.04M-0.06M-0.23M-0.19M-0.03M-0.03M-0.05M-0.06M-0.58M
Asset Writedowns and ImpairmentWritedown
0.02M
Other non-cash itemsOther Non-Cash
0.00M1.06M1.38M0.99M1.17M1.22M1.16M1.23M1.26M1.27M1.30M1.33M
Change in Working Capital
Change in ReceivablesChange Receivables
25.00M-79.31M0.87M14.25M-14.45M0.12M0.05M1.51M-1.43M-0.27M1.44M1.09M
Change in Account PayablesChange Payables
-0.02M0.63M0.02M0.12M1.23M1.13M-2.04M1.61M-1.67M5.98M-4.97M0.56M0.84M-1.36M-0.83M0.31M2.90M-2.29M-1.11M0.33M
Change in Accrued ExpensesChange Accrued Exp.
-0.42M-3.49M-0.16M5.19M-4.68M-0.12M1.42M1.94M5.77M-9.31M2.76M1.17M2.73M-5.12M2.97M2.83M-3.19M-5.13M0.98M0.54M
Change in Other Operating AssetsOther Assets Change
-0.24M0.74M1.23M2.18M0.96M-0.87M5.61M0.06M-1.79M0.09M0.10M3.28M-3.51M-1.06M3.06M-3.15M-2.99M-0.47M2.15M-2.34M
Change in Other Operating LiabilitiesOther Liabilities Change
1.84M52.04M-2.19M-31.36M1.32M18.04M-2.21M-1.68M-7.58M-9.75M-25.60M-6.80M-6.01M-6.27M-4.52M-12.91M-12.33M-3.13M-2.15M-2.30M
Other Working Capital ChangesOther WC Changes
2.08M51.30M-3.42M-33.54M0.36M18.91M-7.81M-1.74M-5.79M-9.84M-25.70M-10.08M-2.50M-5.22M-7.58M-9.76M-9.34M-2.66M-4.30M0.04M
Cash from OperationsCash from Ops.
11.20M34.43M-18.49M-16.21M-12.24M123.57M-0.84M-21.05M-23.76M58.77M-31.58M-27.97M-14.53M-37.90M-33.26M-31.05M-30.26M-33.42M-25.84M-19.67M
Investing Activities
Capital ExpendituresCapex
0.35M0.04M1.24M0.28M0.93M0.51M1.21M0.78M0.76M2.14M0.97M0.26M0.16M0.66M1.11M0.21M0.63M0.01M
Sales of Property, Plant and EquipmentPP&E (Sale)
Change in Property, Plant and EquipmentChange in PP&E
-0.35M-0.04M-1.24M-0.28M-0.93M-0.51M-1.21M-0.78M-0.76M-2.14M-0.97M-0.26M-0.16M-0.66M-1.11M-0.21M-0.63M-0.01M
Purchase of InvestmentsInvestments Purchased
19.96M34.89M166.52M28.99M203.85M90.01M40.81M131.02M76.92M37.87M6.64M12.50M43.44M27.41M7.69M
Sale and Maturity of InvestmentsInvestments Sold
10.00M15.00M15.00M5.00M9.00M56.58M109.93M55.03M105.42M103.97M118.78M40.90M41.73M60.55M51.56M42.80M36.94M
Other Investing Activities (as filed)Other investing (as filed)
Cash from Investing ActivitiesCash from Investing
-5.46M-20.00M-36.13M34.72M14.07M14.49M-24.66M-158.30M26.83M-96.07M-35.94M64.35M-27.20M41.20M1.93M34.89M47.42M8.10M15.39M29.27M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
0.23M0.01M0.81M0.02M0.28M31.31M1.55M0.33M0.46M112.86M0.57M0.01M0.57M0.08M0.51M0.09M0.14M3.33M2.91M3.03M
Net Shares Issued and RepurchasedNet Shares Issued
0.23M0.01M0.81M0.02M0.28M31.31M1.55M0.33M0.46M112.86M0.57M0.01M0.57M0.08M0.51M0.09M0.14M3.33M2.91M3.03M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.23M0.01M0.81M0.02M0.28M31.31M1.55M0.33M0.46M112.86M0.57M0.01M0.57M0.08M0.51M0.09M0.14M3.33M2.91M3.03M
Other financing activities (as filed)
Cash from Financing ActivitiesCash from Financing
0.23M0.01M0.81M0.02M0.28M31.31M1.55M0.33M0.46M112.86M0.57M0.01M0.57M0.08M0.51M0.09M0.14M3.33M2.91M3.03M
Additional items
Change in Cash
5.96M14.44M-53.81M18.53M2.10M169.36M-23.95M-179.02M3.53M75.56M-66.95M36.40M-41.16M3.39M-30.82M3.93M17.30M-21.99M-7.55M12.64M
Ending Cash Balance
119.21M133.65M79.84M98.38M100.47M269.84M245.89M66.86M70.40M145.95M79.00M115.40M74.24M77.63M46.81M50.74M68.04M46.05M38.51M51.14M
Free Cash FlowFCF
10.85M34.39M-19.73M-16.48M-13.18M123.06M-2.05M-21.83M-24.52M56.63M-32.55M-28.23M-14.68M-38.55M-34.37M-31.26M-30.89M-33.43M-25.84M-19.67M
Net Cash FlowNCF
5.96M14.44M-53.81M18.53M2.10M169.36M-23.95M-179.02M3.53M75.56M-66.95M36.40M-41.16M3.39M-30.82M3.93M17.30M-21.99M-7.55M12.64M

Voyager Therapeutics Cash Flow Statement API

Pull Voyager Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=VYGR&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY